Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 7/20 | 0.34 |
| ▸ | CES1 | P23141 | 6/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15156214 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL8442314 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL1707472 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL2389036 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL15326061 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL10000307 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL23560381 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL2725276 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL22277214 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL19462783 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400784-A1 | Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition | LG CHEM, LTD. (KR) | 2024-12-05 | — | — | US | claimed |
| US-20240392094-A1 | Method for Screening Solvent for Polyvinyl Chloride Extraction, Recycling Method for Waste Material, and Recycled Polyvinyl Chloride and Composition | LG CHEM, LTD. (KR) | 2024-11-28 | — | — | US | claimed |
| CN-117897439-A | Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition | 株式会社LG化学 | 2024-04-16 | — | — | CN | claimed |
| WO-2023033601-A1 | METHOD FOR SCREENING SOLVENT FOR POLYVINYL CHLORIDE EXTRACTION, RECYCLING METHOD FOR WASTE MATERIAL, AND RECYCLED POLYVINYL CHLORIDE AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | claimed |
| WO-2023033605-A1 | METHOD FOR SCREENING SOLVENT FOR EXTRACTING POLYVINYL CHLORIDE, METHOD FOR RECYCLING WASTE, RECYCLED POLYVINYL CHLORIDE, AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | claimed |
| US-20240400784-A1 | Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition | LG CHEM, LTD. (KR) | 2024-12-05 | — | — | US | disclosed |
| US-20240392094-A1 | Method for Screening Solvent for Polyvinyl Chloride Extraction, Recycling Method for Waste Material, and Recycled Polyvinyl Chloride and Composition | LG CHEM, LTD. (KR) | 2024-11-28 | — | — | US | disclosed |
| WO-2023033601-A1 | METHOD FOR SCREENING SOLVENT FOR POLYVINYL CHLORIDE EXTRACTION, RECYCLING METHOD FOR WASTE MATERIAL, AND RECYCLED POLYVINYL CHLORIDE AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023033605-A1 | METHOD FOR SCREENING SOLVENT FOR EXTRACTING POLYVINYL CHLORIDE, METHOD FOR RECYCLING WASTE, RECYCLED POLYVINYL CHLORIDE, AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | disclosed |
| US-9902985-B2 | Chemoenzymatic methods for synthesizing moenomycin analogs | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160280732-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-09-29 | — | — | US | disclosed |
| US-9273084-B2 | Moenomycin analogs, methods of synthesis, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150119561-A1 | CHEMOENZYMATIC METHODS FOR SYNTHESIZING MOENOMYCIN ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-30 | — | — | US | disclosed |
| US-20150119354-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-30 | — | — | US | disclosed |
| US-20150079618-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-19 | — | — | US | disclosed |
| WO-2013151697-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013152277-A2 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013152279-A1 | CHEMOENZYMATIC METHODS FOR SYNTHESIZING MOENOMYCIN ANALOGS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-10-10 | — | — | WO | disclosed |
| EP-1509536-A1 | FLUORINATED PHOSPHONIC ACIDS | 3M Innovative Properties Company (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003102003-A1 | FLUORINATED PHOSPHONIC ACIDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119561-A1 | CHEMOENZYMATIC METHODS FOR SYNTHESIZING MOENOMYCIN ANALOGS | CYP51A1, COASY, MRM1 | CES2 895/4885LPAR1 4525/4885LPAR3 4476/4885 |
| US-20150119354-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | RDX, RPS4X, RPS4Y1 | CES2 2161/4885LPAR1 3529/4885LPAR3 1920/4885 |
| US-20160280732-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | RDX, RPS4X, MLX | CES2 2395/4885LPAR1 3138/4885LPAR3 1426/4885 |
| US-20150079618-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | MAGT1, GALNT1, NMT1 | CES2 714/4885LPAR1 3910/4885LPAR3 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.